Sony, M3, Inc. and Illumina, Inc. have agreed to form a collaboration to launch a "genome information platform" in Japan.
Sony and M3 plan to establish P5, Inc. with Illumina as a
minority investor, by the end of February, 2014.
Genome research, which analyzes human genetic data alongside
medical and other information, has the capacity to lead to
breakthroughs in identifying the origins of diseases, as well
as the development of new medicines and methods of treatment.
There is growing anticipation for advances in the field of
personalized medicine, where medication or treatments are
optimized for the individual patient, and this is an area
where genome research findings are expected to play an
increasingly important role.
The new company's "genome information platform" business will
provide a genome analysis service for research institutions
and enterprises in Japan. It will also aggregate genome data
with related information such as medical data to support
research in areas where genome data is applied. Going
forward, the scope of P5 Inc.'s business is expected to extend
beyond medical research, to provide a service platform that
supports the use of genetic data and medical information for
personalized medicine and healthcare services for individual